Patient Power®
Get Email Alerts!
Health Topics
Multiple Myeloma Health Center
Health Center Home Audio Programs Videos Conference Coverage
  • ASH 2011
    • Live Events
  • SCCA Myeloma Town Hall 2011
    • Search by Keyword:
    Search by Health Topic:
    View all Health Topics >
    Spring Survey 2012 Results

    Ask the Expert about the Latest Myeloma News

    PROGRAM DETAILS:

    Multiple Myeloma Specialist Robert Orlowski, M.D. joins Andrew to answer patients’ questions about the newest developments in myeloma, particularly with regards to the latest drug therapies and ideas about stem cell transplants, both for the newly-diagnosed and relapsed patient.

    Dr. Orlowski, section head in multiple myeloma at M. D. Anderson Cancer Center, covers several subject areas in this dense and highly detailed interview. These topic include: Developments for patients who might not be transplant candidates; Pre-transplant induction therapy; Maintenance therapies; Developments in the relapsed and refractory setting; Controlling side effects; Deciding about a transplant; and the newest drug combinations, especially with Velcade and Revlimid.

    Dr. Orlowski explains that myeloma is not just one disease but a combination of several different diseases, and based on the cytogenetic profile, patients may have a disease that can behave differently. He contends patients need to have routine cytogenetics in addition to the standard tests because certain cytogenetic abnormalities may lead to myeloma and be the foundation for more targeted therapies. The number of drugs available to myeloma patients is increasing, and the modeling systems for evaluating drugs and their efficacy against multiple myeloma are improving. This translates to more effective drugs and numerous more options for patients to explore in finding a treatment plan that aggressively fights the disease and allows the patient to maintain a high quality of life.

    Andrew and Dr. Orlowski tackle several questions in this hour-long interview to give myeloma patients an idea of the current state of the disease and where the research is headed.

    Get Email Updates:

    Get updated automatically when new content about Multiple Myeloma has been posted.
    Privacy Policy
    Multiple Myeloma
    EXPERTS & GUESTS:
    Robert Orlowski, M.D., Ph.D. Robert Orlowski, M.D., Ph.D.
    Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, MD Anderson Cancer Center
    Dr. Robert Z. Orlowski is Associate Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine and medical oncology.  Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the... more >

    TRANSCRIPT:

    1. Introduction
    2. An Expert Covers the Recent Development in Five Key Areas in Multiple Myeloma
    3. Balancing Successful Frontline Treatments and the Need for Transplants
    4. Maintenance Therapies and Addressing Different Side Effects
    5. Options for Patients in the 75 Year Age Range
    6. Addressing the Recommended Diagnostic Tests for Multiple Myeloma
    7. Finding a Foundation of Drugs, Including Velcade & Revlimid
    8. Managing Bone Pain and Possible Causes
    9. Can Multiple Myeloma be Inherited?
    10. Understanding the Light Chain Concept
    11. Experimental Drug LBH589, LBH289
    12. Statistics Concerning Transplant versus Revlimid Alone
    13. Combination Treatments
    14. Harvesting Stem Cells and Deferring Transplant
    15. Final Comments

    RELATED LINKS: